2021 World Conference on Lung Cancer (Posters)-FP09. Phase II Randomized Trial to Evaluate Prednisone Taper With or Without Nintedanib for the Treatment of Radiation Pneumonitis

FP09. Phase II Randomized Trial to Evaluate Prednisone Taper With or Without Nintedanib for the Treatment of Radiation Pneumonitis

Back to course

Video Transcription

Video Summary

This presentation discusses the results of a phase 2 randomized controlled trial on the use of Nintendonib for the treatment of radiation pneumonitis. Radiation pneumonitis is a common toxicity of radiation treatment, leading to symptoms such as cough, fever, and respiratory insufficiency. The study aimed to determine whether Nintendonib, a multiple tyrosine kinase inhibitor, would decrease the incidence of acute exacerbations and long-term pulmonary function decline in patients with radiation pneumonitis. The study involved 30 eligible patients, and while there was a trend towards greater freedom from pulmonary exacerbations with Nintendonib, the difference was not statistically significant. The study was limited by low accrual, and further evaluation of Nintendonib is needed. Secondary endpoints will be reported in the future.

Asset Subtitle

Zachary R Moore

Meta Tag

Speaker Zachary R Moore

Topic Novel Therapeutics and Targeted Therapies

Keywords

phase 2

randomized controlled trial

Nintendonib

radiation pneumonitis

tyrosine kinase inhibitor